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Are patients with congestive heart
failure entitled to receive palliative
care?
Abstract
When, in 1963, J.M. Hinton published his article on the suffering that accompanies dying, by no means did
he confine his observation to patients who suffered from oncological conditions. Quite the contrary, as in his
essay we can find an explicit statement which says that the suffering of patients dying from cardiac or renal
insufficiency is even greater than for patients in the terminal stages of cancer [1]. That article sparked off the
development of charitable organizations in Great Britain which took care of oncological patients. This was
the reason why palliative medicine was and still is associated with people dying from cancer. It has been
more than 50 years since the publication of Hilton's work and from that we have rediscovered the forgotten
part of the author's message and begun to realize that patients can ask for help not because of a particular
disease, but because of the suffering that accompanies his dying. Modern palliative medicine has developed
based on the care of oncological patients. For this reason, and despite the fact that the aim of this article is
to draw attention to non-oncological patients, we cannot avoid referring to the problems of patients with
cancer.
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Palliative care is directed to those patients com-
ing close to the end of their lives. Each incurable
and progressing chronic disease may cause suffer-
ing and, eventually, death. Patients diagnosed with
heart failure are faced with a shortened life expect-
ancy when compared to that of the general popula-
tion. The yearly death rate for patients with heart
failure depends on the  disease advancement and
fluctuates from 5% to 60% [2]. Diseases which re-
sult in the death of the patient are described by
death trajectories, i.e. the expected scenario for the
end of life. Patients suffering from heart failure die
from the progression of dysfunction of the heart as
a pump, from the mechanism of sudden cardiovas-
cular death or from non-cardiogenic reasons relat-
ing to coexisting diseases. The stage  of heart fail-
ure advancement is translated into the distribution
of the causes of death: the majority of patients with
less advanced forms of the disease die more sud-
denly (around 60% of deaths) than patients in the
more advanced stages (23% of deaths). A reverse
relationship is found in proportion of deaths caused
by the progression of heart insufficiency as a pump
(28% of deaths in moderate stages of the disease,
44% in advanced stages) [3]. Dying from the heart's
as a pump insufficiency is not necessarily the conse-
quence of  steady progressive deterioration of the
heart function. Gradual disease progression is usu-
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are discharged without any real plan for further
assistance. [5] The first step in improving the quali-
ty of treatment for patients with congestive heart
failure would be to get better communication with
such patients, then learn to respect their wishes
("learn about the needs of your patient, and then
think if and how you can satisfy them"). The three
principles that cardiologists should learn from pal-
liative medicine professionals are listed below: 1.
Active listening 2. The ability to convey bad news 3.
Therapeutic dialogue. [6] The study that evaluated
the quality of life in patients with heart failure in
the last 48–72 hours of their life (based on accounts
of bereaved families) demonstrated that 66% of
patients suffered from severe dyspnoea, 45% from
pain and 15% from mental disorientation. More than
40% of the patients in that condition underwent
major medical interventions (feeding through a
stomach tube, mechanical ventilation or resuscita-
tion). Such a large number of interventions is espe-
cially alarming, if we consider that most of the pa-
tients declared that they wanted to die in peace
instead of aggressively fighting for their lives. Only
members of their families were aware of those wish-
es; the emergency teams of healthcare profession-
als were not [7].
The principles of palliative treatment have been
worked out for oncological patients. Since the anti-
cancer treatment itself is often the cause of symp-
toms and a decrease in quality of life, withdrawing
from it may, therefore, bring relief to patients in
the terminal stages of oncological diseases. Con-
sequently, one cannot escape the thought that a
similar reversal of therapy should also apply to
patients with heart failure. In the meantime, the
ally broken by periods of sudden exacerbations. It is
hard to predict whether the present exacerbation is
only temporary episode, or will put an end to the
patient's life. So, the trajectory of the steady pro-
gression of heart insufficiency until the terminal
stage is interrupted by periods of abrupt failure
worsening  and, sometimes, of an unexpected death.
An analysis of the fates of patients with chronic
congestive heart failure demonstrates that the
course of their final period of life, the progression
of the condition and the quality of life they experi-
ence, is difficult to predict and shows many individ-
ual variations. This is one of the key elements that
make the process of qualifying cardiological patients
for symptomatic treatment so problematic [4].
The symptoms which accompany patients with
congestive heart failure resemble those characteris-
tic for people suffering from cancer. A small num-
ber of dissertations dedicated to patients with con-
gestive heart failure demonstrate that such symp-
toms as pain, dyspnoea, sleeplessness, fatigue or
depression are at least as frequent as the same symp-
toms present in the terminal stages of cancer (Table
1). Unfortunately, symptomatic treatment of the
end stage  heart failure today resembles the condi-
tion of health care for terminal cancer patients from
before the era of palliative medicine. The symptoms
in patients with heart failure who approach the end
of life are treated with the help of ambulance crews,
who are called to subsequent attacks of dyspnoea,
syncope  caused by a drop in arterial pressure, ter-
minal pulmonary oedema or the patients’ agony.
As a result of emergency medical help, patients are
sent to the intensive cardiac units, where they re-
ceive standard treatment for acute heart failure and
Table 1. Frequency (in %) of symptom occurrence in the advanced stages of cancer and heart failure — moderate
or severe (in brackets) [5, 13]
Patients’symptom Oncological Heart failure I/II and (III/IV) NYHA
Pain 78 41% (78)
Dyspnoea 61 83 (61)
Mental symptoms
Mood deterioration 59 41 (59)
Sleeplessness 45 (45)
Fear 30
Anorexia 43 21 (43)
Constipation 37 12 (37)
Nausea/vomiting 32 17 (32)
Fatigue 82
Difficulty in movement 65
Oedema 33
NYHA — New York Heart Association
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currently applied treatment for patients with chron-
ic heart failure, albeit bringing a positive effect to
disease progression and/or distant prognosis, is
often the source of a decrease in the intensity of
cardiovascular system problems. Therefore, aban-
doning this type of treatment is neither necessary
nor appropriate. The change in the priority of treat-
ment, from improving distant prognosis and sup-
pressing disease progression into short-term goals,
i.e. improvement of the quality of life and reduc-
tion of symptoms, allows for the use of drugs which
effectively reduce the symptoms of heart failure —
even if they may affect life expectancy. This is the
case with positive inotropic drugs (catecholamine
and inhibitors of phosphodiesterases). Many ran-
domized studies on the effects of these drugs on
the progression of the disease have demonstrated
that they increase the risk of death, although they
effectively reduce the symptoms caused by heart
failure. The key to accepting the use of these drugs
in palliative cardiology is for the cardiologists to
embrace the principle that the struggle for the pro-
longation of life in the final days may not be as
important as the reduction of suffering. It is ac-
cording to this principle that patients with extreme
heart failure receive catecholamine infusions, even
at home for symptoms control, but not for reach-
ing of hemodynamic goals. Published results are
still too few, but essays that evaluate the influence
of these drugs on the symptoms of heart failure in
the final period of life are promising and weigh in
favour of introducing them in palliative cardiolog-
ical treatment [8–11].
Implantable devices (pacemakers and resynchro-
nizing pacemakers — CRT), as well as antiarrhyth-
mic devices (automatic, implantable cardioverter-
defibrillators — ICDs) have become so popular with
patients with heart failure that attending dying pa-
tients who have such apparatus is slowly becoming
a daily sight. Maintaining the ICD stimulation/activ-
ity during the period of dying has raised many
doubts. Families of patients often inquire about the
usefulness of prolonging stimulation or express their
concern about unnecessary prolongation of agony
by an active device. The deactivation of implantable
automatic cardioverter-defibrillators has created
even more controversy, as patients may suffer from
the discharges of ICD. Such devices frequently inter-
vene when patients are dying, which leads to un-
controlled movements of the body. It may cause
great discomfort to the family and lead to fear of
receive electric shock of caregivers. Although the
debate concerning the functions of the devices in
question has become heated, it is beyond any doubt
that the patient, and most likely his or her family,
has the right to demand deactivation of them. Pa-
tients have an undisputed right to decide about
their treatment. They may not, therefore, agree to
start a new therapy but they can also ask to aban-
don a treatment that has already been in progress.
The deactivation of a ICD is an example of such a
decision [12]. Nobody has the right to question this
wish if the patient has the full mental capacity to
ask for the deactivation of this device. It may, how-
ever, be considered which moment is the most ap-
propriate to discuss the issue of  deactivating the
ICD in case when the patient is approaching death.
It seems that the most logical solution is to inform
the patient about the possibility of deactivating the
ICD device before it is implanted. The most impor-
tant element in the interpretation of the decision to
abandon therapeutic activities (especially ICD) at
the end of life is to understand that the cause of
death is the end stage of disease, not a specific
medical intervention. The essence of such action is,
therefore, not to cause death but to prevent the
suffering from increasing [12]. The decision to de-
activate an ICD can be compared to the decision
not to resuscitate. In the case of natural death caused
by extremely advanced and incurable diseases, re-
suscitation is not only illogical but may also be-
come a reason for questioning the ability to assess
the situation in a professional manner. Unfortunate-
ly, everyday clinical practice demonstrates that the
wishes of patients are not respected, be it from fear
of ethical qualification of such behaviour, lack of
confidence that the apparently inevitable deteriora-
tion of a patient's condition can be reversed or the
intention to inform the bereaved family (or, most
likely, to reassure the doctors themselves) that ev-
erything possible was done to save the life of the
patient.
Death is the natural end of life. The diagnosis of
an incurable and progressive disease determines the
time and manner of approaching it. Doctors, mar-
velling at the effectiveness of modern medicine, of-
ten forget that incurable disease eventually reaches
the stage at which death becomes inevitable. They
see their mission as eliminating the disease, not
curing the patient (treating is not a synonym for
curing!). In the meantime, a significant part of the
medical profession equates the dying of patients
with failure of the treatment. The feeling of failure,
so often present with doctors, makes them avoid
talking to patients and their families about the is-
sue. Consequently, patients cannot understand their
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disease and doctors are not aware of the patients'
needs. The knowledge of the course of a disease
enables doctors to take note of the moment when
further heroic struggles for the prolongation of a
patient's life may diminish the comfort of his or her
last days. Mature support of patients who suffer
from fatal diseases should, therefore, consist of a
skilful change to the treatment objective, from
lengthening the prognosis to improving the quality
of life, and eventually to providing as much comfort
in dying as possible.
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